Target intelligence / Profile preview

Glutamate [NMDA] receptor subunit epsilon-2 (GRIN2B) (GRIN2B)

Target
GRIN2B
Molecular classification
Ion channel, Receptor
01

Overview

The Glutamate [NMDA] receptor subunit epsilon-2 (GRIN2B), also known as GluN2B or NR2B, is a critical subunit of N-methyl-D-aspartate (NMDA) receptors, which are heterotetrameric ligand-gated ion channels permeable to calcium and other cations, requiring both glutamate and glycine/D-serine for activation. It assembles with two GluN1 subunits and another GluN subunit (typically GluN2A or GluN2B) to form functional receptors with high calcium permeability, voltage-dependent magnesium block, and slow deactivation kinetics that contribute to synaptic plasticity, learning, memory, and excitatory neurotransmission in the brain. GRIN2B is expressed prominently in forebrain regions, influencing dendritic patterning, cortical circuit refinement, and experience-dependent plasticity, with its overexpression enhancing cognitive performance in animal models. Dysregulation or mutations in GRIN2B are implicated in neurodevelopmental disorders, epilepsy, schizophrenia, and neurodegenerative diseases due to altered synaptic signaling and excitotoxicity. Selective antagonists targeting the GluN1/GluN2B amino-terminal domain interface, such as ifenprodil, provide negative allosteric modulation, offering potential therapies for pain, depression, and stroke, though challenges include psychotomimetic side effects and ensuring specificity amid receptor subtype diversity.

Other names
N-methyl-D-aspartate receptor subunit 2BNMDAR2BNR2BGluN2BNMDA receptor subunit epsilon 2glutamate receptor ionotropic NMDA 2B
02

Mechanism of action

Negative allosteric modulation at GluN1/GluN2B subunit interface, Noncompetitive antagonism, Positive allosteric modulation

03

Biological functions

Signal transductionSynaptic plasticityLearning and memoryExcitatory synaptic transmission
04

Disease associations

Neurodegenerative diseaseNeurodevelopmental disorderEpilepsySchizophrenia
05

Safety considerations

Psychotomimetic effectsNeurotoxicity from excessive calcium influxVoltage-dependent magnesium block challengesToxicity profile issues in clinical trials (e.g., EVT-101)
06

Interacting drugs

Ifenprodil

8 more in the full profile.

07

Biomarkers

GRIN2B genetic variants for neurodevelopmental disorders

Beyond the preview

Go deeper on Glutamate [NMDA] receptor subunit epsilon-2 (GRIN2B) (GRIN2B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate [NMDA] receptor subunit epsilon-2 (GRIN2B) (GRIN2B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call